Select Premarket Movers
Upside
– ELMT +37% (extends its rally following the recent agreement to acquire ams OSRAM’s Schwabmünchen metal-production operations)
– DFTX +11% (Phase 3 Panorama trial met the primary endpoint in generalized anxiety disorder, delivering a statistically significant and clinically meaningful benefit)
– RUM +10% (advances following plans to acquire additional Northern Data shares, lifting its expected ownership to about 98%)
– ARMP +7.6% (FDA grants Breakthrough Therapy designation to AP-SA02 for complicated S. aureus bacteremia)
– CHRW +5.5% (no clear fresh catalyst identified; unusually large premarket move)
– CRWD +5.2%, PANW +4.8%, FTNT +3.5% (cybersecurity names rise as AI-safety warnings reinforce expectations for elevated enterprise security spending)
– NOW +4.6%, CTSH +3.4%, CRM +2.8%, ACN +3.0% (enterprise-software names benefit from a long-software, short-AI-hardware rotation)
– CRBP +4.1% (Phase 1b CANYON-1 obesity trial showed significant weight loss across all doses with a differentiated gastrointestinal safety profile)
Downside
– ETR -17.5% (no clear fresh catalyst identified; unusually large premarket move)
– SLS -12.0% (no clear fresh catalyst identified; high-volume biotech selloff)
– NOK -9.5%, GLW -9.0%, NBIS -8.0%, HPE -8.0%, STX -6.5% (networking, cloud-infrastructure and storage names fall after leading AI executives backed slowing model development)
– AENT -9.5% (pulls back following Friday’s sharp earnings-driven rally)
– AEHR -9.0%, LRCX -8.0%, KLAC -7.0%, AMAT -7.0%, TER -7.0%, INTC -6.5%, AMD -5.5%, MU -5.5%, MRVL -5.5%, AVGO -3.0%, NVDA -2.5% (chip and semiconductor-equipment stocks sell off as AI-development slowdown calls and concerns about plateauing infrastructure spending pressure the hardware trade)
– MSI -7.0% (no clear fresh catalyst identified; unusually large premarket move)
– ORCL -4.5% (AI-capex concerns trigger profit-taking following the recent earnings-driven rally)
Position: None
